Please login to the form below

Not currently logged in
Email:
Password:

ponatinib

This page shows the latest ponatinib news and features for those working in and with pharma, biotech and healthcare.

Takeda's gamble on Ariad pays off with Alunbrig approval

Takeda's gamble on Ariad pays off with Alunbrig approval

Takeda agreed to buy Ariad earlier this year in a $5.2bn deal, which included already-marketed haematological cancer drug Iclusig (ponatinib) as well as a pipeline of oncology candidates headed

Latest news

More from news
Approximately 12 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    treatment Iclusig (ponatinib) - both in the US and Europe. “ ... And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Ariad appoints new board member Ariad appoints new board member

    Ariad will look to benefit Denner's experience as it prepares to grow the market share of leukaemia drug Iclusig (ponatinib).

  • Jonathan Dickinson joins Ariad from BMS Jonathan Dickinson joins Ariad from BMS

    He joins at an important time for Ariad in Europe as it prepares to launch its chronic myeloid leukaemia treatment Iclusig (ponatinib), pending approval from the European Commission (EC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics